Osteoarthritis Therapeutics Market Segmentation:
Drug Type Segment Analysis
The disease-modifying osteoarthritis drugs (DMOADs) segment is estimated to account for the largest share of 40% in the market over the discussed timeframe. DMOADs are positioned in the first-line group of osteoarthritis treatment options because they are indicated to modify disease progression instead of just controlling symptoms. Per the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), DMOADs may improve cartilage health and slow or stop the deterioration of the joint, ultimately, filling a critical unmet need. There is a rise in R&D spending - combined with a regulatory urgency to get innovative therapies to market - is contributing to greater development for DMOADs. Furthermore, more patients understand early intervention and are incurring more symptomatic management, are further increases the growth potential in the segment.
Therapy Type Segment Analysis
The regenerative therapies (stem cell & PRP) segment is poised to dominate the osteoarthritis therapeutics market with a share of 30% during the analyzed period. PRP (platelet-rich plasma) injections and stem cell therapy have the potential to relieve pain and regenerate cartilage. The Arthritis Foundation states that stem cells, along with PRP, can help improve joint function, with fewer side effects than other therapies. As government-funded agreements and clinical trials continue to expand the evidence base for stem cells and PRP therapies, these therapies will continue to be more commonly used in clinical practice.
Route of Administration Segment Analysis
During the examined period, the intra-articular injections segment is expected to hold a 24% market share in the osteoarthritis therapeutics industry. Injections administered directly into the joint (e.g. steroids or hyaluronic acid) will remain a treatment option to try because these injections have a therapeutic effect on the joints being injected. In fact, the Centers for Disease Control and Prevention (CDC) speaks specifically to the use of intra-articular injections in the management of pain and improvement of mobility for patients with osteoarthritis. As long as injections are accepted, easy to give, and paid for by insurance, this sub-segment of injections will continue to be a steady source of revenue.
Our in-depth analysis of the osteoarthritis therapeutics market includes the following segments:
|
Segments |
Subsegments |
|
Drug Type |
|
|
Therapy Type |
|
|
Route of Administration |
|
|
End User |
|
|
Distribution Channel |
|
